These findings are largely consistent with our disproportionality analyses of PRL-related adverse events with antipsychotics, which suggest that risperidone should be discontinued first in OLZ-treated patients with hyperprolactinemia, and that the use of aripiprazole may protect them from this adverse event. Here, PRL is linked to hyperprolactinemia.